Mainz Biomed NV 8-K filings

Quantum Cyber N.V. (QUCY) presents its strategic pivot to autonomous defense, showcasing battle-tested platforms, integrated IP, and US manufacturing capabilities.

Quantum Cyber N.V. has completed the acquisition of a U.S.-based manufacturing facility in Bridgeport, Connecticut, for $2.3 million, marking a significant step in its transition to vertical integration.

Quantum Cyber N.V. announces definitive agreements to acquire a 50,000 sq ft manufacturing facility and equipment in Bridgeport, Connecticut, for $3.2 million, advancing its strategy for domestic defense manufacturing.

Quantum Cyber N.V. has dismissed Reliant CPA PC and appointed Haskell & White LLP as its new independent auditor.

Quantum Cyber N.V. has secured exclusive worldwide rights to Project LightShift's quantum photonic array technology for defense drone applications.

Quantum Cyber N.V. has amended its intellectual property license agreement with BP United Inc., shifting from a supply agreement to manufacturing and consulting services, and retaining a $5 million payment for its own production ramp-up.

Quantum Cyber N.V. has officially regained compliance with Nasdaq's minimum bid price requirement after maintaining a closing price above $1.00 for 10 consecutive business days.

Quantum Cyber N.V. announced the full exercise of outstanding warrants, raising over $15 million to fund R&D, commercialization, and strategic acquisitions, while eliminating all debt.

Mainz Biomed N.V. has rebranded to Quantum Cyber N.V. following a change in control and the issuance of significant new equity.

Mainz Biomed has entered an agreement to sell its next-generation colorectal cancer screening intellectual property for $1.25 million to focus on pancreatic cancer detection.

Mainz Biomed N.V. received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Quantum Cyber aligns its strategy with the Trump Administration's National Cybersecurity Framework, targets quantum and cyber defense acquisitions, and secures an additional $3 million pre-funding from lead shareholder David Lazar, totaling $6 million.

Mainz Biomed N.V. announced a $6 million private placement with investor David Lazar, a strategic shift to pancreatic cancer detection, and significant changes to its board and corporate structure.

Mainz Biomed N.V. announced the full utilization of a $2.15 million at-the-market equity offering, selling 1.73 million ordinary shares.